
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, reporting a 140% increase in net product revenues, reaching $607.6k for FY24, with Q3 FY25 showcasing an even more remarkable 223% year-over-year increase to $438 thousand. The consistent growth in ARAKODA deliveries, which rose by 14% to 1,505 boxes in Q3 FY25, underscores the product's market traction and demand. Additionally, the potential for tafenoquine's combination use due to its favorable safety profile presents further opportunities for diversification and commercialization, enhancing the company's long-term growth prospects.
Bears say
60 Degrees Pharmaceuticals Inc's stock faces a negative outlook primarily due to its significant cash burn, influenced by the developmental stage of its programs and uncertainty regarding collaborative revenue from partners. The company reported a gross loss of approximately $9,000 in Q3 FY24, attributed to a one-time inventory write-off, which sharply contrasts with the prior gross profit of $36,000, indicating fundamental challenges in maintaining profitability. Additionally, uncertainties surrounding regulatory approvals, potential dilution from future financing needs, and the commercial risks associated with diminishing market share and treatment efficacy further exacerbate concerns regarding the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares